Literature DB >> 15019326

Evaluation of patients with scleritis for systemic disease.

Esen Karamursel Akpek1, Jennifer E Thorne, Faqir A Qazi, Diana V Do, Douglas A Jabs.   

Abstract

OBJECTIVE: To evaluate the relationship between associated medical conditions and scleritis-particularly, the timing of the diagnosis of these diseases.
DESIGN: Retrospective case series. PARTICIPANTS: Patients with scleritis presenting to a single center over an 18-year period.
METHODS: Medical records were reviewed for the presence of an associated infectious or rheumatic disease and for the timing of the diagnosis of the systemic disease relative to the presentation for evaluation of the scleritis. MAIN OUTCOME MEASURES: Presence of an associated medical condition and timing of diagnosis relative to that of scleritis.
RESULTS: In a series of 243 patients with scleritis, 44.0% had an associated medical condition: 7.0%, an infection, and 37.0%, a rheumatic disease. The most frequent infection was herpes zoster, and the most frequent rheumatic disease was rheumatoid arthritis, present in 4.5% and 15.2% of patients, respectively. Of the 107 patients with an underlying disease, 77.6% had a previously diagnosed disease, 14.0% had their conditions diagnosed as a result of the initial evaluation, and 8.4% developed a systemic disease during follow-up. Systemic vasculitis was less likely to have been previously diagnosed than other rheumatic diseases (59.1% vs. 83.8%, P = 0.015) and more likely to be diagnosed by the initial diagnostic evaluation (27.3% vs. 8.8%, P = 0.027). Ten patients (4.1%) had a positive antineutrophil cytoplasmic antibody (ANCA) test result without clinical evidence of a systemic vasculitis. Four of 5 patients with a positive cytoplasmic ANCA test result but no clinical evidence of systemic vasculitis required immunosuppressive drugs for control of the scleritis, whereas 1 of the 5 patients with a positive perinuclear ANCA test result required immunosuppressive drugs. Among patients with no evident systemic disease after the initial diagnostic evaluation, the rate of occurrence of a rheumatic disease was 4% per person-year.
CONCLUSIONS: Although associated systemic diseases are frequent among patients with scleritis, the majority are previously diagnosed. Systemic vasculitis is less likely than other rheumatic diseases to have been previously diagnosed. Because vasculitis is a potentially life-threatening disorder, it should be a focus of the diagnostic evaluation.

Entities:  

Mesh:

Year:  2004        PMID: 15019326     DOI: 10.1016/j.ophtha.2003.06.006

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  49 in total

1.  Use of hydroxychloroquine in corticodependent and recurrent scleritis.

Authors:  Célia Maschi; Nathalie Tieulié; Pierre Gastaud; Stéphanie Baillif
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-19       Impact factor: 3.117

2.  Scleritis and multiple systemic autoimmune manifestations in chronic natural killer cell lymphocytosis associated with elevated TCRalpha/beta+CD3+CD4-CD8- double-negative T cells.

Authors:  S Yeh; Z Li; H N Sen; W-K Lim; F Gill; K Perkins; V K Rao; R B Nussenblatt
Journal:  Br J Ophthalmol       Date:  2010-06       Impact factor: 4.638

3.  Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis.

Authors:  H N Sen; R Ursea; R B Nussenblatt; R R Buggage
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

4.  Clinical characteristics and ocular complications of patients with scleritis in Japanese.

Authors:  Rie Tanaka; Toshikatsu Kaburaki; Kazuyoshi Ohtomo; Mitsuko Takamoto; Keiko Komae; Jiro Numaga; Yujiro Fujino; Makoto Aihara
Journal:  Jpn J Ophthalmol       Date:  2018-05-23       Impact factor: 2.447

Review 5.  Ophthalmic manifestations of rheumatologic disease: diagnosis and management.

Authors:  Carisa K Petris; Arghavan Almony
Journal:  Mo Med       Date:  2012 Jan-Feb

6.  Identification of susceptibility SNPs in CTLA-4 and PTPN22 for scleritis in Han Chinese.

Authors:  F Li; X Ma; L Du; L Shi; Q Cao; N Li; T Pang; Y Liu; A Kijlstra; P Yang
Journal:  Clin Exp Immunol       Date:  2019-04-16       Impact factor: 4.330

7.  The association of choroidal thickness with rheumatoid factor and anti-cyclic citrullinated peptide in rheumatoid arthritis.

Authors:  Arif Ülkü Yener; Kubilay Şahin
Journal:  Int Ophthalmol       Date:  2020-01-11       Impact factor: 2.031

Review 8.  Ocular inflammatory diseases associated with rheumatoid arthritis.

Authors:  Mathieu Artifoni; Pierre-Raphaël Rothschild; Antoine Brézin; Loïc Guillevin; Xavier Puéchal
Journal:  Nat Rev Rheumatol       Date:  2013-12-10       Impact factor: 20.543

Review 9.  Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

10.  Clinical features, predisposing factors, and treatment outcomes of scleritis in the Korean population.

Authors:  Seong Joon Ahn; Joo Youn Oh; Mee Kum Kim; Jin Hak Lee; Won Ryang Wee
Journal:  Korean J Ophthalmol       Date:  2010-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.